BMS-911543 JAK2 inhibitor
- Known as:
- BMS-911543 JAK2 suppressor
- Catalog number:
- a-1175
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- ActivBio Active Biochem
- Gene target:
- BMS-911543 JAK2 inhibitor
Related genes to: BMS-911543 JAK2 inhibitor
- Gene:
- JAK2 NIH gene
- Name:
- Janus kinase 2
- Previous symbol:
- -
- Synonyms:
- JTK10
- Chromosome:
- 9p24.1
- Locus Type:
- gene with protein product
- Date approved:
- 1992-04-16
- Date modifiied:
- 2019-04-23
Related products to: BMS-911543 JAK2 inhibitor
Related articles to: BMS-911543 JAK2 inhibitor
- encodes a pivotal component of the IL-23/Th17 signaling axis and represents a validated genetic susceptibility locus for inflammatory bowel disease (IBD), psoriasis, and ankylosing spondylitis. Despite extensive GWAS data, the functional consequences of the full spectrum of missense single-nucleotide variants (SNVs) have not been systematically characterized. This study aimed to identify high-risk missense SNVs through a multi-tool in silico pipeline. - Source: PubMed
Publication date: 2026/06/16
Altintas Kazar Gamze - Indolent systemic mastocytosis (ISM) is an under-recognised cause of secondary osteoporosis, and skeletal fragility may be the only presenting feature, delaying diagnosis. We describe four adults referred to a tertiary endocrinology service for unexplained osteoporosis or low-trauma fractures, in whom systemic mastocytosis (SM) was identified during work-up. All had elevated basal serum tryptase (41.4-87.0 µg/L), bone-marrow biopsy showing atypical mast cells and the D816V variant; cutaneous lesions were absent in every case. Three patients fulfilled WHO 2022 criteria for ISM. The fourth had coexistent V617F-positive post-essential-thrombocythaemia myelofibrosis and was classified as SM with associated haematological neoplasm (SM-AHN); his mast cell clone (tryptase 43.7 µg/L; D816V VAF 0.391%) behaved indolently and contributed clinically through osteoporosis alone, illustrating that an indolent mast cell component can be overlooked when a chronic myeloid neoplasm dominates the picture. Presentations ranged from an isolated low-energy L5 fracture in a 55-year-old man, to multiple vertebral compression fractures despite denosumab in a 71-year-old woman with primary hyperparathyroidism, to severe wasp-sting anaphylaxis in a 43-year-old man. After multidisciplinary review, all received intravenous zoledronic acid with vitamin D repletion; KIT-targeted therapy is under consideration in selected patients. Although causal inferences cannot be drawn from four retrospectively identified cases, the series illustrates how ISM may be missed in unexplained or treatment-refractory osteoporosis-particularly in younger men, those with prior severe anaphylaxis, and those fracturing on antiresorptive therapy-and supports combining basal serum tryptase with high-sensitivity peripheral-blood D816V testing, in line with the WHO/ICC/AIM-ECNM 2022-2024 criteria. Prospective studies are needed. - Source: PubMed
Publication date: 2026/06/01
Jankovski LuciaHerman RokRakusa MatejKopač PeterKačar MarkŠkerget MatevžJanež AndrejJensterle Mojca - Clonal hematopoiesis of indeterminate potential (CHIP) can lead to adverse outcomes and may begin early in life. This study aimed to investigate the association between early-life events and CHIP. In total, 456,658 participants from U.K. Biobank without baseline hematologic malignancies were enrolled. Exposures included 17 early-life events, including reproductive, childhood adversity, and pre-adulthood development factors. CHIP was derived from whole-exome sequencing for mutations in 74 driver genes. Logistic regressions were used to estimate associations between early-life events and the presence of any CHIP or gene-specific CHIP mutations. Overall, 17,513 (3.8%) individuals with any CHIP were identified, among which the most common subtype was (2.4%), followed by (0.6%) and (0.4%). Compared with participants without sexual abuse in childhood, those who experienced such abuse were positively associated with CHIP (OR 1.35, 95% CI 1.02-1.80), especially among , , and mutations. Long-term/recurrent antibiotic use as a child or teenager was positively associated with CHIP (OR 1.11, 95% CI 1.02-1.21), especially among , , and mutations. Sex-specific differences were observed, including sexual abuse associated with -CHIP in males and -CHIP in females and long-term/recurrent antibiotic use associated with -CHIP in males and -CHIP in females. Furthermore, we identified circulating proteomic biomarkers shared by six pairs of early-life factors and gene-specific CHIP mutations, including B2M for sexual abuse and -CHIP. Early-life factors, especially sexual abuse and long-term/recurrent antibiotic use, were positively associated with the presence of CHIP, particularly among specific gene mutations, offering potential targets for susceptibility and pathogenesis exploration. - Source: PubMed
Publication date: 2026/06/17
Yu YuefengWang JunxueSun YingYu BoweiTan XiaoLu YingliXia FangzhenWang Ningjian - Koumine is a bioactive alkaloid derived from the traditional medicinal plant . Although it has demonstrated anti-tumor effects in various cancers, its specific role and mechanism in hepatocellular carcinoma (HCC) remain unclear. This study aims to investigate the anti-HCC effects of Koumine and elucidate the underlying molecular mechanisms. A network pharmacology approach was employed to predict potential targets and pathways of Koumine against HCC. The binding affinities between Koumine and core targets were validated using molecular docking. In vitro, the effects of Koumine on the proliferation, migration, and invasion of HCC cells were assessed, and the expression levels of key proteins were examined. In vivo, the anti-tumor efficacy and toxicity of Koumine were evaluated using a murine xenograft model. Network pharmacology analysis identified 124 potential targets of Koumine against HCC, with 10 core targets (e.g., P38, JAK1, JAK2, GRB2) and key pathways involving MAP2K1, P38, JAK1, and MET being implicated. Molecular docking confirmed strong binding affinities between Koumine and these core targets. In vitro experiments demonstrated that Koumine dose-dependently inhibited the proliferation, migration, and invasion of HCC cells and modulated the expression and phosphorylation of P38. In vivo results showed that Koumine significantly suppressed tumor growth without causing notable toxicity. This study systematically reveals that Koumine exerts its anti-HCC effects by targeting the MAP2K1, P38, JAK1, JAK2, and MET signaling pathways. These findings highlight the potential of Koumine as a novel and safe therapeutic agent for the treatment of hepatocellular carcinoma. - Source: PubMed
Publication date: 2026/05/30
Lin HailingTang YuliShi LingfeiZhu ShengjieYan WenqiangChen WeihongQue Wancai - : The detection of exon 12 mutations is important for the differential diagnosis of myeloproliferative neoplasms (MPN) and is included in the World Health Organization's diagnostic criteria for polycythemia vera (PV). We developed and evaluated a pyrosequencing-based technique to detect somatic mutations in exon 12 and tested the method in a group of PV patients. : PCR and pyrosequencing primers were designed for region exon 12; PCR conditions were optimized for subsequent qualitative and quantitative detection by pyrosequencing. Diagnostic specificity and sensitivity were determined using plasmid controls. Genomic DNA from 145 MPN patients was used to validate the method. : The analytical characteristics of the method were as follows: the limit of blank was 1.2-7.4% and the limit of detection was 3.4-9.9% depending on mutation type. DNA samples from Russian patients with clinical evidence of MPNs were analyzed. In 7 of 145 cases (4.8%) exon 12 mutations were detected. One patient had the mutation I540-E543insdelTCAGAAATGPublication date: 2026/06/06
Pozdysheva ElenaSubbotina TatianaVoytsekhovskaya YanaShalyova AleksandraMartynova ElenaMironov KonstantinAkimkin Vasily